HBM Partners AG

What they fund

HBM Partners funds companies in the biopharma, medtech, diagnostics, and healthcare sectors, with investments ranging from USD 5 to 50 million [1]. The firm supports companies through all stages of development, from early-stage to growth and buy-out financings [1].

• Early-Stage Companies: Targets early-stage but post-seed round opportunities, providing capital to support initial development and growth [2].
• Growth-Stage Companies: Invests in growth-stage companies, helping them scale operations and expand market reach [1].
• Buy-Out Financings: Engages in buy-out financings of private companies, providing capital for strategic acquisitions and expansions [1].
• Public Company Investments: Makes investments in public companies, offering flexibility in capital deployment and potential for significant returns [1].

Credibility: What they fund is based on HBM Partners' official website and a 2022 article in Swiss daily Luzerner Zeitung, which profiled the company's investment strategy [1][2].

Investment thesis

HBM Partners is a leading Swiss healthcare investor managing USD 2.8 billion in assets, focusing on venture, growth, and buy-out financings of private companies, as well as public company investments in biopharma, medtech, diagnostics, and healthcare across Europe, North America, and emerging markets [1]. The firm leverages its experience and global industry network to support portfolio companies through all stages of development, aiming for significant value creation through trade sales and IPOs [1]. Founded in 2001 by former Roche CFO Henri B. Meier, the firm capitalizes on the thesis that Big Pharma is doing less R&D internally and instead acquiring promising biotech companies [2]. Investments usually range between USD 5 to 50 million [1].

• Strategic Acquisitions: Targets companies with high potential for trade sales to Big Pharma, capitalizing on the industry's shift towards external innovation [2].
• Global Reach: Invests across Europe, North America, India, China, and other Emerging Markets, providing a broad geographic diversification [1].
• Value Creation: Supports portfolio companies through all stages of development, leveraging its experience and worldwide industry network to add value [1].
• Public and Private Investments: Engages in both private and public healthcare investments, offering flexibility in capital deployment [1].

Credibility: The investment thesis is derived from HBM Partners' official website and a 2022 article in Swiss daily Luzerner Zeitung, which profiled the company's investment strategy [1][2].

Value add

HBM Partners supports portfolio companies through all stages of development, leveraging its experience and worldwide industry network to add value [1]. The firm's team of experienced professionals sources, analyses, and engages in private and public healthcare investments, providing strategic guidance and operational support [1].

• Strategic Guidance: Provides strategic guidance to portfolio companies, helping them navigate complex healthcare markets and regulatory environments [1].
• Operational Support: Offers operational support, including access to industry experts and networks, to help companies scale and grow [1].
• Capital Deployment: Deploys capital flexibly, supporting companies through various stages of development and providing follow-on funding as needed [1].

Fit verdict: HBM Partners is a strong fit for healthcare companies seeking strategic guidance, operational support, and flexible capital deployment.

Founder diligence script:

• How does HBM Partners leverage its industry network to support portfolio companies?
• What specific operational support does HBM Partners provide to help companies scale and grow?
• How does HBM Partners approach follow-on funding and capital deployment for portfolio companies?

Credibility: Value add is based on HBM Partners' official website and a 2022 article in Swiss daily Luzerner Zeitung, which profiled the company's investment strategy [1][2].

Portfolio focus

HBM Partners has a track-record of over 100 investments that resulted in more than 60 trade sales and IPOs with significant value creation [1]. The firm's portfolio includes companies in biopharma, medtech, diagnostics, and healthcare sectors [1].

• Crystalys Therapeutics: Received a $130 million Series B financing from HBM Partners to advance global Phase 3 development and commercialization of Dotinurad for gout [1].
• Shape Memory Medical: Completed enrollment in the landmark AAA-SHAPE randomized controlled pivotal trial, supported by HBM Partners [1].
• International BM Biomedicine: Acquired by HBM in 2005, expanding the firm's portfolio and capabilities in the healthcare sector [2].

Credibility: Portfolio focus is based on HBM Partners' official website and a 2022 article in Swiss daily Luzerner Zeitung, which profiled the company's investment strategy [1][2].

Notable investments & exits

HBM Partners has a track-record of over 100 investments that resulted in more than 60 trade sales and IPOs with significant value creation [1]. The firm's portfolio includes companies in biopharma, medtech, diagnostics, and healthcare sectors [1].

• Crystalys Therapeutics: Received a $130 million Series B financing from HBM Partners to advance global Phase 3 development and commercialization of Dotinurad for gout [1].
• Shape Memory Medical: Completed enrollment in the landmark AAA-SHAPE randomized controlled pivotal trial, supported by HBM Partners [1].
• International BM Biomedicine: Acquired by HBM in 2005, expanding the firm's portfolio and capabilities in the healthcare sector [2].

Credibility: Notable exits are based on HBM Partners' official website and a 2022 article in Swiss daily Luzerner Zeitung, which profiled the company's investment strategy [1][2].

Strategic implications

HBM Partners' focus on early-stage but post-seed round opportunities suggests a strategic edge in identifying and nurturing high-potential healthcare companies before they reach mainstream recognition. This approach allows the firm to secure favorable valuations and build long-term relationships with portfolio companies.

The firm's global reach and diversified portfolio across Europe, North America, India, China, and other Emerging Markets provide a significant advantage in accessing diverse markets and opportunities. This geographic diversification helps mitigate risks and maximize returns.

HBM Partners' track-record of over 100 investments that resulted in more than 60 trade sales and IPOs with significant value creation demonstrates a strong ability to create value for portfolio companies. This track-record enhances the firm's reputation and attracts high-quality deal flow.

Where they could go further

HBM Partners could enhance its strategy by focusing more on early-stage companies, particularly those in the pre-seed and seed stages. This would allow the firm to identify and nurture high-potential healthcare companies earlier in their development, potentially leading to higher returns.

The firm could improve its operational support for portfolio companies by providing more hands-on assistance in areas such as regulatory compliance, market access, and commercialization. This would help portfolio companies navigate complex healthcare markets and accelerate their growth.

HBM Partners could expand its co-investment network by partnering with more leading healthcare investors and venture capital firms. This would provide additional capital and support for portfolio companies, enhancing their chances of success.